摘要
目的探究水飞蓟宾联合恩替卡韦治疗乙肝肝硬化患者的效果。方法选择2020年9月—2021年9月胶州中心医院门诊收治的乙肝肝硬化患者100例,依据不同治疗方式分成观察组(水飞蓟宾联合恩替卡韦治疗)及对照组(恩替卡韦治疗),各50例。对比两组患者的炎症因子水平、不良反应、HBeAg和HBV-DNA阴转率等情况。结果与对照组的IL-10、IL-2、TNF-α、IL-6相比,观察组的各项炎症因子水平均明显较低,差异有统计学意义(P<0.05);与对照组的HBeAg阴转率15例(30.00%)、HBV-DNA阴转率40例(80.00%)相比,观察组24例(48.00%)、49例(98.00%)明显更高,差异有统计学意义(χ^(2)=3.404、8.273,P<0.05);与对照组发生的不良反应4例(8.00%)比较,观察组的1例(2.00%)较低,但差异无统计学意义(χ^(2)=1.557,P>0.05)。结论针对乙肝肝硬化患者,通过采用水飞蓟宾联合恩替卡韦治疗,能够改善患者的炎症因子水平,提升疾病疗效,明显改善疾病预后,降低不良反应发生率,适合临床推广。
Objective To investigate the effect of silibinin combined with entecavir in the treatment of patients with hepatitis B cirrhosis.Methods A total of 100 patients with hepatitis B cirrhosis who were admitted to the outpatient clinic of Jiaozhou Central Hospital from September 2020 to September 2021 were selected.According to different treatment methods,they were divided into observation group(silibinin combined with entecavir treatment)and con⁃trol group(entecavir treatment),with 50 cases in each group.The levels of inflammatory factors,adverse reactions,HBeAg and HBV-DNA negative conversion rates of the two groups of patients were compared.Results Compared with IL-10,IL-2,TNF-αand IL-6 in the control group,the levels of various inflammatory factors in the observation group were significantly lower,and the difference was statistically significant(P<0.05);compared with the negative conversion rate of HBeAg in the control group of 15 cases(30.00%)and the negative conversion rate of HBV-DNA in 40 cases(80.00%),the observation group of 24 cases(48.00%)and 49 cases(98.00%)were significantly higher,the difference was statistically significant(χ^(2)=3.404,8.273,P<0.05);compared with 4 cases(8.00%)of adverse reac⁃tions in the control group,1 case(2.00%)in the observation group was lower,but the difference was not statistically significant(χ^(2)=1.557,P>0.05).Conclusion For patients with hepatitis B cirrhosis,silibinin combined with entecavir treatment can improve the level of inflammatory factors,improve the efficacy of the disease,significantly improve the prognosis of the disease,and reduce the incidence of adverse reactions which is suitable for clinical promotion.
作者
孙欣祖
邵春芝
韩鹏
SUN Xinzu;SHAO Chunzhi;HAN Peng(Department of Infectious Diseases,Jiaozhou Central Hospital,Qingdao,Shandong Province,266300 China)
出处
《系统医学》
2022年第11期75-78,共4页
Systems Medicine
